Literature DB >> 21110105

Cystic fibrosis Δf508 mutation screening in Brazilian women with altered fertility.

G V F Brunoro1, E V Wolfgramm, I D Louro, I I Degasperi, V C W Busatto, A M S Perrone, M C P Batitucci.   

Abstract

Cystic Fibrosis (CF) is an autosomal recessive disease, caused by mutations in the Cystic Fibrosis Transmembrane Regulator gene (CFTR). The most frequent mutation in CF is ΔF508. The disease is clinically characterized by elevated concentrations of sweat chlorides and abnormally thick mucus. It affects organs such as lung, pancreas, gastrointestinal and reproductive tract. Women with CF commonly present delayed puberty and amenorrhea due to malnutrition. Our objective was to screen the presence of ΔF508 mutation in 24 women with altered fertility. Nine of these women presented reduced fertility without a known cause, four showed polycystic ovaries and two had early menopause. One woman with early menopause was a carrier of the ΔF508 mutation. Our study demonstrates that it is possible that the frequency of CF mutations among patients with altered fertility may be higher than expected. Previous data showed that fibrocystic women can show reduced fertility, maternal mortality associated with pregnancy and increased incidence of spontaneous abortion. We therefore recommend that women with reduced fertility undertake genetic tests for a better evaluation of pregnancy risks and clinical monitoring.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21110105     DOI: 10.1007/s11033-010-0560-x

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  18 in total

1.  Water and electrolytes in cervical mucus from patients with cystic fibrosis.

Authors:  L E Kopito; H J Kosasky; H Shwachman
Journal:  Fertil Steril       Date:  1973-07       Impact factor: 7.329

Review 2.  Cystic fibrosis in pregnancy.

Authors:  N E Kent; D F Farquharson
Journal:  CMAJ       Date:  1993-09-15       Impact factor: 8.262

3.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

4.  Delayed puberty in girls with cystic fibrosis despite good clinical status.

Authors:  M Johannesson; C Gottlieb; L Hjelte
Journal:  Pediatrics       Date:  1997-01       Impact factor: 7.124

Review 5.  Selective activation of cystic fibrosis transmembrane conductance regulator Cl- and HCO3- conductances.

Authors:  M M Reddy; P M Quinton
Journal:  JOP       Date:  2001-07

6.  Biological status of adult patients with cystic fibrosis.

Authors:  M Kosinska; A Szwed; J Cieslik; J Gozdzik; S Cofta
Journal:  J Physiol Pharmacol       Date:  2008-12       Impact factor: 3.011

7.  Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor.

Authors:  R Rozmahel; M Wilschanski; A Matin; S Plyte; M Oliver; W Auerbach; A Moore; J Forstner; P Durie; J Nadeau; C Bear; L C Tsui
Journal:  Nat Genet       Date:  1996-03       Impact factor: 38.330

8.  Identification of the cystic fibrosis gene: chromosome walking and jumping.

Authors:  J M Rommens; M C Iannuzzi; B Kerem; M L Drumm; G Melmer; M Dean; R Rozmahel; J L Cole; D Kennedy; N Hidaka
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

9.  Cystic fibrosis and pregnancy. A national survey.

Authors:  L F Cohen; P A di Sant'Agnese; J Friedlander
Journal:  Lancet       Date:  1980-10-18       Impact factor: 79.321

10.  Analysis of cystic fibrosis transmembrane conductance regulator gene mutations in patients with congenital absence of the uterus and vagina.

Authors:  Lorna S Timmreck; Mark R Gray; Barbara Handelin; Bernice Allito; Elizabeth Rohlfs; Ann J Davis; Gita Gidwani; Richard H Reindollar
Journal:  Am J Med Genet A       Date:  2003-07-01       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.